Hyperglycemia and obesity as determinants of glucose, insulin, and glucagon responses to β-endorphin in human diabetes mellitus

D. Giugliano, T. Salvatore, D. Cozzolino, A. Ceriello, R. Torella, F. D'Onofrio

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The effect of human β-endorphin on plasma glucose, insulin, and glucagon concentrations was studied in patients with noninsulin-dependent diabetes mellitus and in normal subjects. The subjects were divided according to their body weight into lean (body mass index, <25) and obese (body mass index, > 29.5) groups. In lean subjects, infusion of 0.5 mg/h β-endorphin caused significant increases in peripheral plasma glucose and glucagon levels, but no change in plasma insulin. In obese subjects, there was an immediate marked increase in both plasma insulin and glucagon concentrations during the β-endorphin infusion, but the plasma glucose response was lower than that of lean subjects. In lean diabetic patients, β-endorphin produced significant simultaneous increments in both insulin and glucagon concentrations and significantly decreased plasma glucose levels. These hormonal responses to β-endorphin were amplified in the obese diabetic patients. There was a significant correlation (r = 0.61; P <0.01) between fasting plasma glucose levels and the integrated insulin area in response to β-endorphin. The infusion of a lower dose of β-endorphin (0.05 mg/h) in diabetic patients produced similar increments in both insulin and glucagon levels and also decreased plasma glucose concentrations. These results indicate that β-endorphin may have important glucoregulatory effects in man depending on the dose administered, the presence of obesity, and the prevailing plasma glucose concentration.

Original languageEnglish
Pages (from-to)1122-1128
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume64
Issue number6
Publication statusPublished - 1987

Fingerprint

Endorphins
Medical problems
Glucagon
Hyperglycemia
Diabetes Mellitus
Obesity
Insulin
Plasmas
Glucose
Type 2 Diabetes Mellitus
Fasting
Body Mass Index
Body Weight

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Hyperglycemia and obesity as determinants of glucose, insulin, and glucagon responses to β-endorphin in human diabetes mellitus. / Giugliano, D.; Salvatore, T.; Cozzolino, D.; Ceriello, A.; Torella, R.; D'Onofrio, F.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 64, No. 6, 1987, p. 1122-1128.

Research output: Contribution to journalArticle

@article{2ad2d05d89624375b8c8be2b826dc1b7,
title = "Hyperglycemia and obesity as determinants of glucose, insulin, and glucagon responses to β-endorphin in human diabetes mellitus",
abstract = "The effect of human β-endorphin on plasma glucose, insulin, and glucagon concentrations was studied in patients with noninsulin-dependent diabetes mellitus and in normal subjects. The subjects were divided according to their body weight into lean (body mass index, <25) and obese (body mass index, > 29.5) groups. In lean subjects, infusion of 0.5 mg/h β-endorphin caused significant increases in peripheral plasma glucose and glucagon levels, but no change in plasma insulin. In obese subjects, there was an immediate marked increase in both plasma insulin and glucagon concentrations during the β-endorphin infusion, but the plasma glucose response was lower than that of lean subjects. In lean diabetic patients, β-endorphin produced significant simultaneous increments in both insulin and glucagon concentrations and significantly decreased plasma glucose levels. These hormonal responses to β-endorphin were amplified in the obese diabetic patients. There was a significant correlation (r = 0.61; P <0.01) between fasting plasma glucose levels and the integrated insulin area in response to β-endorphin. The infusion of a lower dose of β-endorphin (0.05 mg/h) in diabetic patients produced similar increments in both insulin and glucagon levels and also decreased plasma glucose concentrations. These results indicate that β-endorphin may have important glucoregulatory effects in man depending on the dose administered, the presence of obesity, and the prevailing plasma glucose concentration.",
author = "D. Giugliano and T. Salvatore and D. Cozzolino and A. Ceriello and R. Torella and F. D'Onofrio",
year = "1987",
language = "English",
volume = "64",
pages = "1122--1128",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Hyperglycemia and obesity as determinants of glucose, insulin, and glucagon responses to β-endorphin in human diabetes mellitus

AU - Giugliano, D.

AU - Salvatore, T.

AU - Cozzolino, D.

AU - Ceriello, A.

AU - Torella, R.

AU - D'Onofrio, F.

PY - 1987

Y1 - 1987

N2 - The effect of human β-endorphin on plasma glucose, insulin, and glucagon concentrations was studied in patients with noninsulin-dependent diabetes mellitus and in normal subjects. The subjects were divided according to their body weight into lean (body mass index, <25) and obese (body mass index, > 29.5) groups. In lean subjects, infusion of 0.5 mg/h β-endorphin caused significant increases in peripheral plasma glucose and glucagon levels, but no change in plasma insulin. In obese subjects, there was an immediate marked increase in both plasma insulin and glucagon concentrations during the β-endorphin infusion, but the plasma glucose response was lower than that of lean subjects. In lean diabetic patients, β-endorphin produced significant simultaneous increments in both insulin and glucagon concentrations and significantly decreased plasma glucose levels. These hormonal responses to β-endorphin were amplified in the obese diabetic patients. There was a significant correlation (r = 0.61; P <0.01) between fasting plasma glucose levels and the integrated insulin area in response to β-endorphin. The infusion of a lower dose of β-endorphin (0.05 mg/h) in diabetic patients produced similar increments in both insulin and glucagon levels and also decreased plasma glucose concentrations. These results indicate that β-endorphin may have important glucoregulatory effects in man depending on the dose administered, the presence of obesity, and the prevailing plasma glucose concentration.

AB - The effect of human β-endorphin on plasma glucose, insulin, and glucagon concentrations was studied in patients with noninsulin-dependent diabetes mellitus and in normal subjects. The subjects were divided according to their body weight into lean (body mass index, <25) and obese (body mass index, > 29.5) groups. In lean subjects, infusion of 0.5 mg/h β-endorphin caused significant increases in peripheral plasma glucose and glucagon levels, but no change in plasma insulin. In obese subjects, there was an immediate marked increase in both plasma insulin and glucagon concentrations during the β-endorphin infusion, but the plasma glucose response was lower than that of lean subjects. In lean diabetic patients, β-endorphin produced significant simultaneous increments in both insulin and glucagon concentrations and significantly decreased plasma glucose levels. These hormonal responses to β-endorphin were amplified in the obese diabetic patients. There was a significant correlation (r = 0.61; P <0.01) between fasting plasma glucose levels and the integrated insulin area in response to β-endorphin. The infusion of a lower dose of β-endorphin (0.05 mg/h) in diabetic patients produced similar increments in both insulin and glucagon levels and also decreased plasma glucose concentrations. These results indicate that β-endorphin may have important glucoregulatory effects in man depending on the dose administered, the presence of obesity, and the prevailing plasma glucose concentration.

UR - http://www.scopus.com/inward/record.url?scp=0023236154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023236154&partnerID=8YFLogxK

M3 - Article

VL - 64

SP - 1122

EP - 1128

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 6

ER -